Indian Generics Makers Set To Produce Tamiflu For Patent-Free Nations
This article was originally published in PharmAsia News
Executive Summary
India's drug makers are receiving requests from several countries to supply a generic version of Roche's Tamiflu (oseltamivir) antiviral against the spreading H1N1 flu virus. A Cipla official says it alone has proposals from at least three countries to supply 1.5 million doses of the drug. Indian generics makers are free to produce the drug and ship it to countries where Roche does not have patent protection. India's patent office rejected a Roche application for protection that would have prevented production. (Click here for more
You may also be interested in...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.